Fosamprenavir

ARV U.S. Brand Name

Lexiva

ARV Abbreviation(s)

FPV

U.S. FDA Label

ARV Class

First U.S. Approval

October 20, 2003

U.S. Manufacturer

Formulations

Strength	Formulation	Image	Description	Boosted
700 mg	Capsules	X	Pink, film-coated, capsule-shaped, biconvex tablet, with “GX LL7” debossed on one face	No
	Oral Solution	X	White to off-white grape-bubblegum-peppermint–flavored suspension, contains 50 mg of fosamprenavir as fosamprenavir calcium equivalent to approximately 43 mg of amprenavir in each 1 mL.	No

Generic Available?

Yes

Other Reference Links

U.S. Guidelines Links

Adult dosing

1400 mg twice daily, with or without 100mg or 200 mg ritonavir

Treatment naive adults

700 mg BID plus 100 mg ritonavir BID

PI-experience adults. See guidelines for use in pregnant adults.

Pediatric dosing

45 mg/kg plus ritonavir 7 mg/kg Oral Solution <11 kg

30 mg/kg plus ritonavir 7 mg/kg Oral Solution 11 kg - <15 kg

23 mg/kg plus ritonavir 7 mg/kg Solution 15 kg - <20 kg

18 mg/kg plus ritonavir 7 mg/kg Oral Solution ≥20 kg

Assistance Programs

Displaying 1 - 3 of 3

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Nevirapine FPV 578	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of fosamprenavir		Not studied	700 mg fosamprenavir BID with 100 mg ritonavir BID	No significant change	Do not use with fosamprenavir alone. Ritonavir boosted fosamprenavir (700 / 100 mg BID) can be considered
Nevirapine FPV 577	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of fosamprenavir	Decreased fosamprenavir effects	Nevirapine AUC decreased 46%; Cmax decreased 42%	1400 mg BID	Fosamprenavir AUC decreased 33%; Cmax decreased 25%; Cmin decreased 35%	Do not use with fosamprenavir alone. Ritonavir boosted fosamprenavir (700 / 100 mg BID) can be considered
Fosamprenavir